改变儿科心力衰竭:低剂量萨库比特里尔/瓦尔萨坦的疗效
Hui Zha1, Xuejia Zhai2, Lin Wang1
1Department of Pediatric, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Current problems in cardiology
|November 7, 2024
概括
低剂量萨库比特里尔/瓦尔沙坦通过改善喷射率和减少心脏大小,有效治疗儿科心力衰竭. 仔细调整剂量对于控制血压和优化儿童治疗结果至关重要.
科学领域:
- 心脏病学 心脏病学
- 儿科医学 儿科医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 儿童心力衰竭是一个重大的临床挑战,与高发病率和死亡率有关.
- 目前对儿科心力衰竭的治疗选择有限,需要探索新的治疗药物.
研究的目的:
- 为了评估sacubitril/valsartan在患有心力衰竭的儿科患者中的疗效.
- 为了确定适合和安全的剂量方案,在这个人群中,sacubitril/valsartan.
主要方法:
- 对儿童心力衰竭患者进行了回顾性审查,这些患者对传统疗法没有反应.
- 萨库比特里尔/瓦尔萨坦的剂量是每天两次0.2 mg/kg,根据血压监测逐渐增加 (目标为70/50 mmHg).
- 使用心声学 (左心室喷射率,左心室大小),NT-proBNP水平和药物度) 评估有效性.
主要成果:
- 包括23名患有扩张性心肌病和晚期心力衰竭的儿科患者.
- 平均sacubitril/valsartan剂量为1.84 mg/kg/day,导致左心室喷射率 (LVEF) 显著改善,并在6个月内减少左心室大小.
- NT-proBNP水平显著下降,表明心脏应变减少. 活性代谢物萨库比特利酸盐的峰值度约为1.6mg/kg.
结论:
- 低剂量萨库比特里尔/瓦尔萨坦在治疗儿科心力衰竭方面表现出显著的疗效.
- 调整剂量策略对于优化治疗效果至关重要,包括改善LVEF和减少心脏尺寸,同时避免低血压.
- 萨库比特里尔/瓦尔萨坦为患有心力衰竭的儿童提供了一个有前途的新治疗途径.
更多相关视频
09:23Shunt Surgery, Right Heart Catheterization, and Vascular Morphometry in a Rat Model for Flow-induced Pulmonary Arterial Hypertension
Published on: February 11, 2017
16.7K
07:41Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device
Published on: July 20, 2022
1.8K
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
391
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
391
01:22Heart Failure Drugs: Diuretics
345
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
345
01:22Heart Failure Drugs: β-Blockers
319
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
319
01:28Mitral Regurgitation IV: Nursing Management
3
Mitral regurgitation (MR) is a condition where the mitral valve does not close properly, leading to the backward flow of blood from the left ventricle into the left atrium during systole. This condition can arise from various causes, including rheumatic fever, infective endocarditis, or degenerative valve disease. Effective nursing management is crucial to optimizing patient outcomes and involves comprehensive assessment and targeted interventions.Comprehensive Patient AssessmentA detailed...
3
01:22Dose-Response Relationship: Potency and Efficacy
4.2K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.2K